A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of EDP 305 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Adult Female Subjects
Latest Information Update: 21 Sep 2022
At a glance
- Drugs EDP 305 (Primary) ; Ethinylestradiol; Norgestimate
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
Most Recent Events
- 23 Jul 2019 Status changed from recruiting to completed.
- 26 Dec 2018 New trial record